Accueil > Actualités > Case Study - Why Big Pharma should listen in to conversations about an Ebola (...)
Case Study - Why Big Pharma should listen in to conversations about an Ebola vaccinedimanche 21 décembre 2014
With advances in technology and the growth of social networks, it has become easier to monitor critical situations like the Ebola epidemic and take appropriate measures. Tracking the real-life progress of the epidemic via social platforms has become an important part of fighting Ebola and recognizing new outbreaks as early as possible. The rise of social media in developing nations has also made tracking the spread of diseases and information related to those diseases easier than ever.
For pharmaceutical companies, this means they can greatly benefit from monitoring the online conversation surrounding epidemics like Ebola, especially with regards to their research and development of new drugs or vaccines.
This case study will look at how the conversation about the epidemic evolved over time, at the pharmaceutical companies involved in research and development of new medication, how the public perceives them in the context of the Ebola outbreak and how pharma companies can use these insights to manage their reputations.